{"DataElement":{"publicId":"5509026","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy CML Status Type","preferredDefinition":"A description of the best response to therapy for CML.","longName":"2946463v1.0:2939785v1.2","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2939785","version":"1.2","preferredName":"CML Status Type","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals.  Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival._A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"2939785v1.2","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Second or greater chronic phase","valueDescription":"Greater Than or Equal To Integer::2 Chronic Phase","ValueMeaning":{"publicId":"3137658","version":"1","preferredName":"Greater Than or Equal To Integer::2 Chronic Phase","longName":"3137658","preferredDefinition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.: A number with no fractional part.::2: (KRAHN-ik) Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Greater Than or Equal To","conceptCode":"C61583","definition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chronic Phase","conceptCode":"C28262","definition":"Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"903AB2C5-7CC9-97E4-E040-BB89AD437A94","latestVersionIndicator":"Yes","beginDate":"2010-09-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2010-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FC50BAB-F50E-44D5-E053-F662850A18FF","beginDate":"2010-09-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"Disease status follows a previous HCT","valueDescription":"Disease or Disorder Status Post Previous Hematopoietic Stem Cell Transplantation","ValueMeaning":{"publicId":"3304806","version":"1","preferredName":"Disease or Disorder Status Post Previous Hematopoietic Stem Cell Transplantation","longName":"3304806","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.: A condition or state at a particular time.: Happening at a time subsequent to a reference time; later in time or order.: Occurring prior to something else.: Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.): The grafting of tissues from one individual to another or place to place within a single individual.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Previous","conceptCode":"C25627","definition":"Occurring prior to something else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematopoietic Stem Cell","conceptCode":"C12551","definition":"Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1E1F4AC-6E42-B404-E040-BB89AD4305F4","latestVersionIndicator":"Yes","beginDate":"2011-11-16","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FC50BAB-F518-44D5-E053-F662850A18FF","beginDate":"2010-09-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"Chronic phase","valueDescription":"Chronic Phase","ValueMeaning":{"publicId":"2939871","version":"1","preferredName":"Chronic Phase","longName":"2939871","preferredDefinition":"(KRAHN-ik) Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Phase","conceptCode":"C28262","definition":"Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"737AF4EE-8867-027B-E040-BB89AD430180","latestVersionIndicator":"Yes","beginDate":"2009-09-13","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FC50BAB-F522-44D5-E053-F662850A18FF","beginDate":"2009-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"Cytogenetic relapse","valueDescription":"Cytogenetics Relapse","ValueMeaning":{"publicId":"2939870","version":"1","preferredName":"Cytogenetics Relapse","longName":"2939870","preferredDefinition":"Cytogenetics is the study of chromosomes and the related disease states caused by numerical and structural chromosome abnormalities.: The return of signs and symptoms of cancer after a period of improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetics","conceptCode":"C16487","definition":"The branch of biology that studies the cellular aspects of heredity, especially the chromosomes. Includes the study of disease states caused by numerical and structural chromosome abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Relapse","conceptCode":"C18265","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"737AF4EE-8842-027B-E040-BB89AD430180","latestVersionIndicator":"Yes","beginDate":"2009-09-13","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FC50BAB-F52C-44D5-E053-F662850A18FF","beginDate":"2009-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"Molecular relapse","valueDescription":"Molecular Relapse","ValueMeaning":{"publicId":"2939869","version":"1","preferredName":"Molecular Relapse","longName":"2939869","preferredDefinition":"Molecular; relating to or produced by or consisting of molecules.: The return of signs and symptoms of cancer after a period of improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular","conceptCode":"C25574","definition":"Relating to or produced by or consisting of molecules.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Relapse","conceptCode":"C18265","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"737AF4EE-881C-027B-E040-BB89AD430180","latestVersionIndicator":"Yes","beginDate":"2009-09-13","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FC50BAB-F536-44D5-E053-F662850A18FF","beginDate":"2009-09-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"First chronic phase","valueDescription":"First Chronic Phase","ValueMeaning":{"publicId":"2939792","version":"1","preferredName":"First Chronic Phase","longName":"2939792","preferredDefinition":"Preceding all others in time or space or degree.: (KRAHN-ik) Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chronic Phase","conceptCode":"C28262","definition":"Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73556589-0320-4C8B-E040-BB89AD436005","latestVersionIndicator":"Yes","beginDate":"2009-09-11","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FC50BAB-F54A-44D5-E053-F662850A18FF","beginDate":"2010-09-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"Accelerated phase","valueDescription":"Accelerated Phase Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"3304774","version":"1","preferredName":"Accelerated Phase Chronic Myelogenous Leukemia","longName":"3304774","preferredDefinition":"A phase of chronic myelogenous leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3173","definition":"A phase of chronic myeloid leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1E102A3-9517-BD84-E040-BB89AD432297","latestVersionIndicator":"Yes","beginDate":"2011-11-16","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FC50BAB-F554-44D5-E053-F662850A18FF","beginDate":"2010-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"Blast phase","valueDescription":"Blast Phase Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"2675142","version":"1","preferredName":"Blast Phase Chronic Myelogenous Leukemia","longName":"2675142","preferredDefinition":"An advanced phase of chronic myelogenous leukemia.  It is characterized a. by the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or b. an extramedullary proliferation of blasts, and/or c. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C9110","definition":"An advanced phase of chronic myeloid leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38DBE882-E438-674F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-29","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FC50BAB-F55E-44D5-E053-F662850A18FF","beginDate":"2009-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"Complete hematologic response (CHR)","valueDescription":"Complete Hematologic Response","ValueMeaning":{"publicId":"5540398","version":"1","preferredName":"Complete Hematologic Response","longName":"5540398","preferredDefinition":"The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Hematologic Response","conceptCode":"C123575","definition":"The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FA1F895-F1B8-05B5-E053-F662850AA504","latestVersionIndicator":"Yes","beginDate":"2016-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3FC50BAB-F59A-44D5-E053-F662850A18FF","beginDate":"2016-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"ONEDATA","dateModified":"2016-10-26","deletedIndicator":"No"},{"value":"Hematologic relapse","valueDescription":"Recurrent Hematologic Malignancy","ValueMeaning":{"publicId":"6535898","version":"1","preferredName":"Recurrent Hematologic Malignancy","longName":"6535898","preferredDefinition":"The reemergence of a hematologic malignancy after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Hematologic Malignancy","conceptCode":"C27358","definition":"The reemergence of a hematologic malignancy after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78F88E5D-81D9-5B95-E053-F662850ABBB1","latestVersionIndicator":"Yes","beginDate":"2018-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-10-24","modifiedBy":"ONEDATA","dateModified":"2018-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"78F88E5D-81F2-5B95-E053-F662850ABBB1","beginDate":"2018-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-10-24","modifiedBy":"ONEDATA","dateModified":"2018-10-24","deletedIndicator":"No"},{"value":"Complete hematologic response (CHR) preceded by accelerated phase and/or blast phase","valueDescription":"Prior Accelerated Phase of Disease And/Or Blastic Phase Complete Hematologic Response","ValueMeaning":{"publicId":"6617419","version":"1","preferredName":"Prior Accelerated Phase of Disease And/Or Blastic Phase Complete Hematologic Response","longName":"6617419","preferredDefinition":"Earlier in time or order.: The phase of a disease characterized by laboratory and clinical findings that indicate rapid progression.: Used to indicate that either or both of two items or options may be valid.: Sudden increase of the number of blasts in the bone marrow and/or peripheral blood in a patient with a history of chronic leukemia.: The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Accelerated Phase of Disease","conceptCode":"C36155","definition":"The phase of a disease characterized by laboratory and clinical findings that indicate rapid progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Blastic Phase","conceptCode":"C115160","definition":"Sudden increase of the number of blasts in the bone marrow and/or peripheral blood in a patient with a history of chronic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Hematologic Response","conceptCode":"C123575","definition":"The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FACE6F4-821E-226D-E053-F662850AF4CB","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7FACE6F4-8237-226D-E053-F662850AF4CB","beginDate":"2019-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","deletedIndicator":"No"},{"value":"Complete hematologic response (CHR) preceded only by chronic phase","valueDescription":"Prior Chronic Phase Complete Hematologic Response","ValueMeaning":{"publicId":"6617420","version":"1","preferredName":"Prior Chronic Phase Complete Hematologic Response","longName":"6617420","preferredDefinition":"Earlier in time or order.: Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.: The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chronic Phase","conceptCode":"C28262","definition":"Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Hematologic Response","conceptCode":"C123575","definition":"The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FACE6F4-8245-226D-E053-F662850AF4CB","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7FACE6F4-825E-226D-E053-F662850AF4CB","beginDate":"2019-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2939784","version":"1","preferredName":"CML Status Type","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C3174:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73556589-0280-4C8B-E040-BB89AD436005","latestVersionIndicator":"Yes","beginDate":"2009-09-11","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-11","modifiedBy":"ONEDATA","dateModified":"2009-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FC50BAB-F4F8-44D5-E053-F662850A18FF","latestVersionIndicator":"Yes","beginDate":"2016-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-26","modifiedBy":"KUMMEROA","dateModified":"2019-01-17","changeDescription":".Added PV for another context. AK 10/24/18 Added 2 PVs for 2402r4. AK 1/17/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"CMLF_DABR_cml_best_resp_thrpy","type":"NMDP_FN","context":"NHLBI"},{"name":"CMLF_PHPI_cml_best_resp_thrpy","type":"NMDP_FN","context":"NHLBI"},{"name":"CMLP_LTHM_cml_best_resp_thrpy","type":"NMDP_FN","context":"NHLBI"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"RECUR_PROG_SITE_TP","type":"COG GDE Short Name","context":"COG"}],"ReferenceDocuments":[{"name":"What was the best outcome of","type":"Preferred Question Text","description":"What was the best outcome of therapy for CML?","url":null,"context":"NHLBI"},{"name":"Compared to the disease status prior to the preparative regimen, what was the best response to HCT since the date of the last report?","type":"Alternate Question Text","description":"Compared to the disease status prior to the preparative regimen, what was the best response to HCT since the date of the last report?","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy","type":"Application Standard Question Text","description":"Best response to line of therapy","url":null,"context":"NHLBI"},{"name":"What was the best response to HCT or cellular therapy since the date of the last report?","type":"Alternate Question Text","description":"What was the best response to HCT or cellular therapy since the date of the last report?","url":null,"context":"NHLBI"},{"name":"What was the best response to therapy?","type":"Alternate Question Text","description":"What was the best response to therapy?","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy","type":"Alternate Question Text","description":"Best response to line of therapy","url":null,"context":"NHLBI"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Site of relapse:","url":null,"context":"COG"},{"name":"OG CRF TEXT 2","type":"Alternate Question Text","description":"Type of relapse:","url":null,"context":"COG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E848884-3DB0-7BE4-E053-F662850A724F","latestVersionIndicator":"Yes","beginDate":"2016-10-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-10","modifiedBy":"KUMMEROA","dateModified":"2021-06-17","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}